1. Sponsored by:
26-27 April 2017
Hotel Kabuki, San Francisco
HARNESSING THE POWER OF BIG DATA
IN PRECISION MEDICINE
www.healthnetworkcommunications.com/biodatawest
Organised by:
3. Dear future delegate,
The worlds of science and technology have never been so closely intertwined. The potential and applications of bio data
are limitless. From patients tracking their own symptoms to doctors virtually assessing patient needs; from personalized
sequencing of cancer genomes to defeating aging through AI, it is safe to say the pharma industry will never be the
same again.
BioData World West 2017 is bringing scientific innovation to the forefront with tracks on:
1. Genomics
2. Precision Medicine
3. NEW AI track put together in partnership with Merck
In San Francisco, over 200 participants will gather in the beating heart of innovative tech to discuss disruptive approaches
being used to drive drug development, personalized medicine, and inevitably, the clinic. This unique conference gathers
clinicians, bioinformaticians, pharmaceutical companies, start-ups and government policy advisors under one roof!
Our expert speaking faculty for 2017 includes:
Healthcare is joining the big data club. With the advent of high-throughput genomics, the debut of artificial intelligence,
and more, the industry is starting to tackle the futuristic era it finds itself in.
I look forward to meeting you in San Francisco on April 26 - 27, 2017.
Edward Glanville
Conference Director
T/ +44 (0) 207 0921196
E/ Edward.Glanville@healthnetworkcommunications.com
IN PARTNERSHIP WITH
Atul Butte
Director, Institute for
Computational Health
Sciences
UCSF
Ronald Przygodzki
Director
Genomic Medicine
Implementation, U.S.
Department of Veterans
Affairs
Sean Grimmond
Director of Research, &
Bertalli Chair of Cancer
Medicine
University of Melbourne
Centre for Cancer
Research
Alex Zhavoronkov
CSO
The Biogerontology
Research Foundation
CEO
InSilico Medicine Inc
Wendy Rubinstein
Director of N.I.H. Genetic
Testing Registry and Senior
Scientist
NIH
Christina Waters
CEO
RARE
Sean Khozin
Thoracic oncologist and
Senior Medical Officer
F.D.A
Elizabeth Baca
Senior Health Advisor
Governor’s Office of
Planning and Research
State of California
Governor’s Office of
Planning and Research
Slava Akmaev
Senior Vice President &
Chief Analytics Officer
BERG Health
Jean Zenklusen
Director, The Cancer
Genome Atlas, Centre for
Cancer Genomics, Office of
the Director
National Cancer Institute
Register your team online today to save! www.healthnetworkcommunications.com/biodatawest
4. Register online today to reserve your place! www.healthnetworkcommunications.com/biodatawest
Featured sessions include:
GENOMICS & HEALTH
“Storing and processing genome data will exceed the computing
challenges running of YouTube and Twitter, biologists warn.”
The growth of global data, not only within healthcare, is one of the greatest success stories of the
past 15 years. By 2020, there will be 5.200 GB of data for every person on Earth with genomic data
predicted to be largest component of this data (each genome takes up 100GB.) Big Data and Genomics
is transforming drug development, empowering the patient and redesigning the clinic.
Bringing big data and genomics to unlock cures for rare diseases
• Connecting millions of data points to deliver ground breaking healthcare
• Data is frozen knowledge. It’s up to us to bring the heat to melt it
• Investing in data
Elements of MVP (Million Veterans Project), where we want to go in the
future, and our strategy to transform genomic efforts into the clinic.
• Building one of the world’s largest medical databases by safely collecting blood
samples and health information from one million Veteran volunteers.
• How to manipulate one of the largest genomic data sets in the world
• Future use of MVP data to enhance the health of veterans
Leading Australia’s largest genome research effort into Cancer genome
sequencing, transcriptome analysis of disease and development, and
development of tools for genome analysis
• Focus on finding new ways to automate and sort these large and important data
sets
• Understanding the molecular signature of each individual patient we can make more
informed decisions
• Fostering global collaboration to defeat cancer
Ronald Przygodzki
Director
Genomic Medicine
Implementation, U.S.
Department of Veterans
Affairs
Atul Butte
Director, Institute for
Computational Health
Sciences
UCSF
Sean Grimmond
Director of Research, &
Bertalli Chair of Cancer
Medicine
University of Melbourne
Centre for Cancer
Research
5. Scott Marshall (Noppe)
Brandon
Senior Consultant
Open Medicine Institute
Scott Kahn
Ex CIO VP Informatics
Illumina
Nicholas Marko
Founding board member of
the International Society for
Chief Data Officers, Director
of Neurosurgical Oncology
Geisinger Health System
James Mills Barbeau
Assoc. Professor, Brown
University Alpert Medical
School, Director of
Laboratory Medicine
Lifespan Academic
Medical Center
Katherine Reid
Nutrition Researcher/
Counselor
Open Medicine Institute
David Haussler
Distinguished Professor of
Biomolecular Engineering
U.C.S.C.
Christina Waters
CEO
RARE
Atul Butte
Director, Institute for
Computational Health
Sciences
UCSF
Ronald Przygodzki
Director
Genomic Medicine
Implementation, U.S.
Department of Veterans
Affairs
Sean Grimmond
Director of Research, &
Bertalli Chair of Cancer
Medicine
University of Melbourne
Centre for Cancer
Research
Martin Akerman
CTO, Scientific Collaborator
at CSHL
Envisagenics and
Cold Spring Harbor
Laboratory
Laura van ‘t Veer
Professor Laboratory
Medicine and Associate
Director Applied Genomics
for the Cancer Center at
UCSF; co-founder Agendia
Carolyn Wilson
Associate Director for
Research
FDA
Peter White
Director, Division of
Biomedical Informatics
Cincinnati Children’s
Hospital Medical Center
Jim Broach
Director of the Penn State
Institute for Personalized
Medicine
University of
Pennsylvania School of
Medicine
Andreas M. Kogelnik
Director, CEO
Open Medicine Institute
Jean Zenklusen
Director, The Cancer
Genome Atlas, Centre for
Cancer Genomics, Office of
the Director
National Cancer Institute
James Cai
Global Head of Data Science
Roche
Sàndor Szalma
Head of Data and
Bioinformatics
Takeda
Ruth March
VP and Head Personalised
Healthcare & Biomarkers
AstraZeneca
Cinnamon Bloss
Assistant Professor
UC San Diego
Kevin McKernan
Head of Research
Courtagen Life Sciences
Inc
Aaron Black
Director of Informatics
Inova Translational
Medicine Institute
Rick Dewey
Senior Director, Head of
Translational Genetics
Regeneron Genetics
Center
Daryl Waggot
Data Scientist,
Stanford University
Keith Elliston
Chief Executive Officer
Transmart Foundation
David Smith
Professor of Laboratory
Medicine and Pathology
Chairman of the Technology
Assessment Group Center
for Individualized Medicine
Mayo Clinic
Jeffrey Bond
Lead Bioinformatician,
NMTRC
Spectrum Health System
Amalio Telenti
MD, PhD, Chief Data
Scientist
Human Longevity
Catherine Brownstein
Manager, Molecular
Genomics Core Facility
Boston Children’s
Hospital
Speakers include:
6. Register online today to reserve your place! www.healthnetworkcommunications.com/biodatawest
PRECISION MEDICINE
Healthcare is defined by paradigm shifts in technology.
With each new technological advance, we come one step closer to the goal of every human living a
healthy life free of disease. Precision medicine has the potential to cure diseases previously thought
incurable. It has the potential to enhance the quality of life for millions of patients around the world who
traditional medications simply aren’t working for. It has the potential to eliminate side-effects as each
drug is tailored to a specific subset of individuals. Even President Obama showcased his belief in the
potential when he announced the Precision Medicine Initiative (PMI) through the NIH.
Uncover advances in precision medicine from across the globe in countries like the US, Singapore,
Australia, Canada, Sweden, and Finland.
Genome Asia, sequencing 100,000 genomes across the Asian population
• Despite being >40% of the world’s population - are significantly underrepresented in
current genomic studies and reference genome databases even though the unique
genetic diversity prevalent in South and East Asia provides a valuable source of
clinical insights
• Developing a commitment to open information
• Understand biology of disease and enable new therapeutic options which will have
global impact.
Advancing precision medicine through collaboration and big data
• Innovation in the public sector to foster health through multiple projects including
public-private partnerships
• Accelerating precision medicine in California
• Fostering a culture for collaboration and development
How to drive NGS into the clinic
• What are the roadblocks to driving NGS into the clinic?
• How systems are allowing for the provision of a personalized healthcare system
• The greater picture
Stephan C. Schuster
Research Director
SCELSE
Professor at Nanyang
Technological University,
Singapore
Elizabeth Baca
Senior Health Advisor
Governor’s Office of Planning
and Research State of
California Governor’s
Office of Planning and
Research
Wendy Rubinstein
Director of N.I.H. Genetic
Testing Registry and Senior
Scientist
NIH
Featured sessions include:
7. Novel sequencing-based assays as biomarkers of disease
• Prediction of novel biomarkers using big data
• Genomic technologies to identify the genetic etiology and underlying mechanisms of
human disease in order to define precision therapies for diseased individuals
• Predictive genomic signatures of response to therapy, and novel sequencing-based
assays as biomarkers of disease
The Big data hype: How to deliver next generation research at new depths on
Migraines and Schizophrenia
• Is big data smoke and mirrors or does it really have a place in modern healthcare
• Breaking from the conscious and understanding data sets that are beyond
comprehension without big data.
• Seeing the big data picture and treatment of diseases that have not been understood
until the big data revolution in healthcare.
Ali Torkamani
Director of Genome
Informatics and Drug
Discovery
The Scripps Translational
Science Institute
Megan Doerr
Principal Scientist
Governance
Sage Bionetworks
Aarno Palotie
Research Director
Institute for Molecular
Medicine Finland (FIMM)
Paul Glimsher
Director, Institute for the
Interdisciplinary Study of
Decision Making &
Professor
NYU
Director
Kavli HUMAN Project
Trevor Hawkins
Independent Board Member
& Strategy/Technology
Advisor
Various
Stephan C. Schuster
Research Director
SCELSE
Professor at Nanyang
Technological University,
Singapore
Hannah Bayer
Chief Scientific Officer
The Human Project
Aristides Patrinos
Deputy Director for
Research
New York University
Center for Urban Science
and Progress
Christina Waters
CEO
RARE
Speakers include:
Big Data and Genomics: Empowering citizens to share health data through
mobile technolog
• Who are the past, present, and future health data stakeholders?
• What is the current state of health data sharing via mobile platforms?
• In what ways do app-mediated research studies support citizen empowerment in
research?
8. Join them today by registering online! www.healthnetworkcommunications.com/biodatawest
PRECISION MEDICINE
Katherine Reid
Nutrition Researcher/
Counselor
Open Medicine Institute
Daniel Jones
Professor and Vice Chair,
Division of the Molecular
Pathology
Ohio State University
Comprehensive Cancer
Center
Jeffrey Bhasin
Clinical Epigenomics Leader
Cleveland Clinic
David Smith
Professor of Laboratory
Medicine and Pathology
Chairman of the Technology
Assessment Group Center
for Individualized Medicine
Mayo Clinic
Catherine Brownstein
Manager, Molecular
Genomics Core Facility
Boston Children’s
Hospital
Manuel Corpas
Scientific Lead
Repositive
Kevin Fitzpatrick
CEO
Cancer LinQ
Lyn Fitzgerald
Senior Vice President, U.S
& Global Development at
National Comprehensive
Cancer Network®
National Comprehensive
Cancer Network
Elizabeth Nardi
Quality of Oncology Care
Fellow
National Comprehensive
Cancer Network
Wendy Rubinstein
Director of N.I.H. Genetic
Testing Registry and Senior
Scientist
NIH
Jeanette McCarthy
Adjunct Associate
Professor
Duke University
Natalie Thorne
Clinical Bioinformatics
and Genomics Project
Manager
Melbourne Genomics
Health Alliance
Megan Doerr
Principal Scientist
Governance
Sage Bionetworks
Gordon Okimoto
Co-Director
University of Hawaii
Cancer Center
Claudio Carini
Global Head Clinical
Immunology and Biomarkers
Pfizer
Sean Khozin
Senior Medical Officer
FDA
Elizabeth Baca
Senior Health Advisor
Governor’s Office of
Planning and Research
State of California
Governor’s Office
of Planning and
Research
Laura Pisani
Assistant Professor,
Pediatrics - Medical
Genetics
Columbia University
Medical Center
Yuval Itan
Research Associate
Rockefeller University
Laura van ‘t Veer
Professor Laboratory
Medicine and Associate
Director Applied Genomics
for the Cancer Center,
UCSF
co-founder, Agendia
Marie-Pierre Dubé
Director
Beaulieu-Saucier
Université de Montréal
Pharmacogenomics
Centre
Catherine Brownstein
Manager
Molecular Genomics
Core Facility, Boston
Children’s Hospital
Jean Zenklusen
Director, The Cancer
Genome Atlas, Centre for
Cancer Genomics, Office of
the Director
National Cancer Institute
Pravin Mishra
Director, Precision
Genomics Core Laboratory
& R&D, Intermountain
Healthcare, Dixie
Regional Medical
Center
John Mattison
Assistant Medical
Director/CMIO
Kaiser Permanente
Aarno Palotie
Research Director
Institute for Molecular
Medicine Finland (FIMM)
Jennifer Hall
Chief, Institute of Precision
Cardiovascular Medicine
American Heart
Association
Ali Torkamani
Director of Genome
Informatics and Drug
Discovery
The Scripps Translational
Science Institute
Steve Miller
Director
UCSF Clinical
Microbiology Laboratory
Adam Godzik
Director
Sanford-Burnham
Medical Research
Institute
Anna Berry
Scientific Director of
Personalized Medicine
and Medical Director of
Molecular Diagnostics
Swedish Cancer
Institute
9. Register online today to reserve your place! www.healthnetworkcommunications.com/biodatawest
INTRODUCING THE NEW AI TRACK
In partnership:
We have collaborated with Merck to put together an exciting additional track in 2017. We’ll be diving into
the world of Artificial Intelligence and examining how this technology is changing the face of medicine.
Mark A. DePristo
Head of deep learning for
genetics and genomics
Google
Slava Akmaev
Senior Vice President &
Chief Analytics Officer
Berg Health
Sourav Bandyopadhyay
Assistant Professor
UCSF
Sergio E Baranzini
Professor Weill Institute
for Neurosciences
UCSF
Debjit Ray
Postdoctoral
researcher Sandia
National Labs
Speakers include:
Featured sessions include:
Defeating aging through genomics
• Effective antiaging methodologies through big data and genomics
• Understanding systems using genome wide association studies to allude to new
mechanisms to aging.
• Treating aging as a disease
Artificial Intelligence in Drug Discovery and Aging Research
• Insilicos Next generation mechanisms for drug development using Artificial Intelligence
to discover new targets.
• Breaking innovation stagnation in pharmaceuticals with AI
• Working beyond human cognition and innovation using Insilco mechanisms
Aubrey De Grey
Chief Science Officer and
Co-Founder
Sens Foundation Inc
Alex Zhavoronkov
(CSO, The Biogerontology
Research Foundation) CEO
InSilico Medicine Inc
The Big data hype: How to deliver next generation
research at new depths on Migraines and Schizophrenia
• We review the history and taxonomy of machine learning and
artificial intelligence
• We will introduce deep learning, covering both what it is and why
its so exciting.
• We will then discuss in detail two concrete applications to life
sciences problems:
• Calling SNP and indel variants in next-generation sequencing data
• Detection of diabetic retinopathy from fundus images of the eye
Philip Nelson
Director, Software
Engineering
Google
10. THE A-TO-Z OF BIODATA
Cinnamon Bloss
Assistant Professor
UC San Diego
Claudio Carini
Global Head Clinical
Immunology and Biomarkers
Pfizer
Daniel Jones
Professor and Vice Chair,
Division of the Molecular
Pathology
Ohio State University
Comprehensive Cancer
Center
Catherine Brownstein
Manager, Molecular
Genomics Core Facility
Boston Children’s
Hospital
Christina Waters
CEO
RARE
Alex Zhavoronkov
(CSO, The Biogerontology
Research Foundation) CEO
InSilico Medicine Inc
Ali Torkamani
Director of Genome
Informatics and Drug
Discovery
The Scripps
Translational Science
Institute
Aarno Palotie
Research Director
Institute for Molecular
Medicine Finland (FIMM)
Aaron Black
Director of Informatics
Inova Translational
Medicine Institute
Adam Godzik
Director
Sanford-Burnham
Medical Research
Institute
James Cai
Global Head of Data
Science
Roche
James Mills Barbeau
Assoc. Professor, Brown
University Alpert Medical
School, Director of
Laboratory Medicine
Lifespan Academic
Medical Center
Jean Zenklusen
Director, The Cancer
Genome Atlas, Centre for
Cancer Genomics, Office of
the Director
National Cancer Institute
Hannah Bayer
Chief Scientific Officer
The Human Project
Jeanette McCarthy
Adjunct Associate Professor
Duke University
Kevin Fitzpatrick
CEO
Cancer LinQ
Kevin McKernan
Head of Research
Courtagen Life Sciences
Inc
Laura Pisani
Assistant Professor,
Pediatrics - Medical
Genetics
Columbia University
Medical Center
Laura van ‘t Veer
Professor Laboratory
Medicine and Associate
Director Applied Genomics
for the Cancer Center at
UCSF
co-founder, Agendia
Lyn Fitzgerald
Senior Vice President, U.S
& Global Development at
National Comprehensive
Cancer Network®
National Comprehensive
Cancer Network
Daryl Waggot
Data Scientist
Stanford University
Amalio Telenti
MD, PhD, Chief Data
Scientist
Human Longevity
Jeffrey Bhasin
Clinical Epigenomics Leader
Cleveland Clinic
Manuel Corpas
Scientific Lead
Repositive
Ronald Przygodzki
Director, Genomic Medicine
Implementation, U.S.
Department of Veterans
Affairs
Olexandr Isayev
Professor
University of North
Carolina at Chapel Hill
Paul Glimsher
Director, Institute for the
Interdisciplinary Study
of Decision Making &
Professor, NYU
Director, Kavli HUMAN
Project
Peter White
Director, Division of
Biomedical Informatics
Cincinnati Children’s
Hospital Medical Center
Pravin Mishra
Director, Precision Genomics
Core Laboratory & R&D,
Intermountain Healthcare
Dixie Regional Medical
Center
Rick Dewey
Senior Director, Head of
Translational Genetics
Regeneron Genetics
Center
Sergio E Baranzini
Professor Weill Institute for
Neurosciences
UCSF
Slava Akmaev
Senior Vice President &
Chief Analytics Officer
Berg Health
Sourav Bandyopadhyay
Assistant Professor
UCSF
Stephan C. Schuster
Research Director, SCELSE
Professor at Nanyang
Technological University,
Singapore
Steve Miller
Director
UCSF Clinical
Microbiology Laboratory
Trevor Hawkins
Independent Board Member
& Strategy/Technology
Advisor
Various
11. Don’t hesitate – register now! www.healthnetworkcommunications.com/biodatawest
Debjit Ray
Postdoctoral researcher
Sandia National Labs
Elizabeth Baca
Senior Health Advisor
Governor’s Office of
Planning and Research
State of California
Governor’s Office of
Planning and Research
Elizabeth Nardi
Quality of Oncology Care
Fellow
National Comprehensive
Cancer Network
David Haussler
Distinguished Professor of
Biomolecular Engineering
U.C.S.C.
David Smith
Professor of Laboratory
Medicine and Pathology
Chairman of the Technology
Assessment Group Center
for Individualized Medicin
Mayo Clinic
Atul Butte
Director, Institute for
Computational Health
Sciences
University of California,
San Francisco
Aubrey De Grey
Chief Science Officer and
Co-Founder
Sens Foundation Inc
Andreas M. Kogelnik
Director, CEO
Open Medicine Institute
Anna Berry
Scientific Director of
Personalized Medicine
and Medical Director of
Molecular Diagnostics
Swedish Cancer Institute
Aristides Patrinos
Deputy Director for
Research
New York University
Center for Urban Science
and Progress
Jennifer Hall
Chief, Institute of Precision
Cardiovascular Medicine
American Heart
Association
Jim Broach
Director of the Penn State
Institute for Personalized
Medicine
University of
Pennsylvania School of
Medicine
John Mattison
Assistant Medical Director/
CMIO
Kaiser Permanente
Jeffrey Bond
Lead Bioinformatician,
NMTRC
Spectrum Health System
Katherine Reid
Nutrition Researcher/
Counselor
Open Medicine Institute
Marie-Pierre Dubé
Director
Beaulieu-Saucier
Université de Montréal
Pharmacogenomics
Centre
Martin Akerman
CTO, Scientific Collaborator
at CSHL
Envisagenics and
Cold Spring Harbor
Laboratory
Gordon Okimoto
Co-Director
University of Hawaii
Cancer Center
Carolyn Wilson
Associate Director for
Research
FDA
Keith Elliston
Chief Executive Officer
Transmart Foundation
Megan Doerr
Principal Scientist
Governance
Sage Bionetworks
Nancy Brown
CEO
American Heart
Association
Natalie Thorne
Clinical Bioinformatics and
Genomics Project Manager
Melbourne Genomics
Health Alliance
Nicholas Marko
Founding board member of
the International Society for
Chief Data Officers, Director
of Neurosurgical Oncology
Geisinger Health System
Ruth March
VP and Head Personalised
Healthcare & Biomarkers
AstraZeneca
Sàndor Szalma
Head of Data and
Bioinformatics
Takeda
Scott Kahn
Ex CIO VP Informatics
Illumina
Scott Marshall (Noppe)
Brandon
Senior Consultant
Open Medicine Institute
Sean Grimmond
Director of Research, &
Bertalli Chair of Cancer
Medicine
University of Melbourne
Centre for Cancer
Research
Sean Khozin
Senior Medical Officer
FDA
Wendy Rubinstein
Director of N.I.H. Genetic
Testing Registry and Senior
Scientist
NIH
Yuval Itan
Research Associate
Rockefeller University
12. Register online today to reserve your place! www.healthnetworkcommunications.com/biodatawest
DAY 1
WEDNESDAY 26th
APRIL 2017, SAN FRANCISCO
1/4
OPENING KEYNOTE PLENARY
08:45 Opening remarks:
CHAIR: Atul Butte, Director, Institute for Computational Health Sciences, University of California, San Francisco
09:00 Bringing big data and genomics to unlock cures for rare diseases
• Connecting millions of data points to deliver ground breaking healthcare
• Data is frozen knowledge. It’s up to us to bring the heat to melt it
• Investing in data
Atul Butte, Director, Institute for Computational Health Sciences, University of California, San Francisco
09:20 Elements of MVP (Million Veterans Project), where we want to go in the future, and our strategy to transform genomic efforts
into the clinic.
• Building one of the world’s largest medical databases by safely collecting blood samples and health information from one million Veteran
volunteers.
• How to manipulate one of the largest genomic data sets in the world
• Future use of MVP data to enhance the health of veterans
Ronald Przygodzki, Director, Genomic Medicine Implementation, U.S. Department of Veterans Affairs
09:40 Leading Australia’s largest genome research effort into Cancer genome sequencing, transcriptome analysis of disease and
development, and development of tools for genome analysis
• Focus on finding new ways to automate and sort these large and important data sets
• Understanding the molecular signature of each individual patient we can make more informed decisions
• Fostering global collaboration to defeat cancer
Sean Grimmond, Director of Research, & Bertalli Chair of Cancer Medicine, University of Melbourne Centre for Cancer Research
Speed networking and morning refreshments10:00
10:40 Facilitating a culture of responsible and
effective sharing of cancer genome
data
• Every disease is a rare disease at the
molecular level
• Researchers will not have access to
enough molecular test results for any rare
disease without international data sharing
• Those of us involved in the Global Alliance
for Genomics and Health are building
successful mechanisms for international
data sharing
David Haussler, Distinguished Professor of
Biomolecular Engineering, U.C.S.C.
GENOMICS AND HEALTH
Deep learning in medicine: an
introduction and applications to next-
generation sequencing and disease
diagnostics
• We review the history and taxonomy of
machine learning and artificial intelligence
• We will introduce deep learning, covering
both what it is and why its so exciting.
• Calling SNP and indel variants in next-
generation sequencing data
• Detection of diabetic retinopathy from
fundus images of the eye
Mark A. DePristo, Head of deep learning for
genetics and genomics, Google
Philip Nelson, Director, Software Engineering,
Google
ARTIFICIAL INTELLIGENCEPRECISION MEDICINE
Genome Asia, sequencing 100,000
genomes across the Asian population
• Despite being >40% of the world’s
population - are significantly
underrepresented in current genomic
studies and reference genome databases
even though the unique genetic diversity
prevalent in South and East Asia provides
a valuable source of clinical insights
• Developing a commitment to open
information
• Understand biology of disease and enable
new therapeutic options which will have
global impact.
Stephan C. Schuster, Research Director,
SCELSE, Professor at Nanyang Technological
University, Singapore
11:00 PANEL DISCUSSION: Collaborative
Scientific Innovation and Translational
Medicine
Christina Waters, CEO, RARE
David Haussler, Distinguished Professor of
Biomolecular Engineering, U.C.S.C.
David Smith, Professor of Laboratory Medicine and
Pathology Chairman of the Technology Assessment
Group Center for Individualized Medicine, Mayo
Clinic
James Mills Barbeau, Assoc. Professor, Brown
University Alpert Medical School, Director of
Laboratory Medicine, Lifespan Academic Medical
Center
Katherine Reid, Nutrition Researcher/Counselor,
Open Medicine Institute
Scott Marshall (Noppe) Brandon, Senior
Consultant, Open Medicine Institute
PANEL DISCUSSION: The Future of
‘Omics how they come together where
these fields and technologies/trends
are going why phenomics matter
Hannah Bayer, Chief Scientific Officer,
The Human Project
Aristides Patrinos, Deputy Director for Research,
New York University Center for Urban Science
and Progress
Paul Glimsher, Director, Institute for the
Interdisciplinary Study of Decision Making &
Professor, NYU; Director, Kavli HUMAN Project
Trevor Hawkins, Independent Board Member &
Strategy/Technology Advisor, Various
13. DAY 1
WEDNESDAY 26th
APRIL 2017, SAN FRANCISCO
2/4
INTERACTIVE ROUNDTABLES
12:00 Cleaning E-Health records and raw
data. Inventing the car before the
wheel.
Scott Kahn, Ex CIO VP Informatics, Illumina
How to implement AI tools
Thomas Clozel, co-founder, OWKIN
Translation of NGS to the Clinic
Christina Waters, CEO, RARE
David Smith, Professor of Laboratory Medicine
and Pathology Chairman of the Technology
Assessment Group Center for Individualized
Medicine, Mayo Clinic
Catherine Brownstein, Manager, Molecular
Genomics Core Facility, Boston Children’s
Hospital
Katherine Reid, Nutrition Researcher/Counselor,
Open Medicine Institute
Translating Big Data into Clinical Trial
Designs
Jurgen Hammer, Global Head of Data Science and
Center and Head of Pharma Research and Early
Development Informatics, Roche
Eric Lai, Senior Vice President, Head of
Pharmacogenomics and Companion Diagnostics,
Takeda
Developing innovative AI solutions for
clinical research
Translating screening genomic panels
in cancer into focused monitoring
assays
Daniel Jones, Professor and Vice Chair, Division of
the Molecular Pathology, Ohio State University
Comprehensive Cancer Center
IT Infrastructure and HPC in Genomics
Nicholas Marko, Founding board member of the
International Society for Chief Data Officers,
Director of Neurosurgical Oncology, Geisinger
Health System
Defeating aging through AIHow do we drive epigenetics into the
clinical practice?
Jeffrey Bhasin, Clinical Epigenomics Leader,
Cleveland Clinic
How to drive forwards innovation
in precision medicine through
collaboration.
Scott Marshall (Noppe) Brandon,
Senior Consultant, Open Medicine
InstituteHealth System
The future of AI in pharmaceutical
development
Efficient and ethical genome data
sharing
Manuel Corpas, Scientific Lead, Repositive
Networking Lunch12:20
13:40 Uniting the translational and clinical
research communities by developing an
integrated i2b2/tranSMART platform in
the cloud
• Sharing clinical data on a grand scale
• How to create a unilateral data sharing and
collaborative system
• The future of TranSMART
Keith Elliston, Chief Executive Officer, Transmart
Foundation
Artificial Intelligence in Drug Discovery
and Aging Research
• Insilicos Next generation mechanisms
for drug development using Artificial
Intelligence to discover new targets.
• Breaking innovation stagnation in
pharmaceuticals with AI
• Working beyond human cognition and
innovation using Insilco mechanisms
Alex Zhavoronkov, (CSO, The Biogerontology
Research Foundation) CEO, InSilico Medicine Inc
How to drive NGS into the clinic
• What are the roadblocks to driving NGS
into the clinic?
• How systems are allowing for the
provision of a personalized healthcare
system
• The greater picture
Wendy Rubinstein, Director of N.I.H. Genetic
Testing Registry and Senior Scientist, NIH
14:00 Genomics: Improving Scientific Insights
from Clinical Trials
• Advances in genome sequencing
technologies have driven a dramatic
increase in collecting genomics data,
where genome sequencing in clinical trials
is one of the fast growing applications.
• Industry-wide pain points are slowing the
streamlined integration of genomics data
into clinical trials.
• Clinical Trial Genomics provides at-scale,
secure upload of genomics data and
automated linking with study clinical data,
machine-learning standardization of both
data across studies, and turnkey analytics
for immediately actionable hypotheses for
on-going studies.
Jason Mezey, PhD, Professor of Computational
Biology and Genetic Medicine, Cornell/Weill
Cornell Medicine, Lead Architect of CTG,
Medidata Solutions
Defeating aging through genomics
• Effective antiaging methodologies
through big data and genomics
• Understanding systems using genome
wide association studies to allude to new
mechanisms to aging.
• Treating aging as a disease
Aubrey De Grey, Chief Science Officer and Co-
Founder, Sens Foundation Inc
Big Data in Cancer Care, Hopes, Dreams
and Hard Realities
• Big data has the potential to drive
powerful insights in Cancer Care
• Clinical trials enroll only 3% of cancer
patients, we need to learn from every
patient
• Oncologists are seeking a “rapid learning
system” that can democratize access to
the most current clinical information.
Kevin Fitzpatrick, CEO, Cancer LinQ
14. DAY 1
WEDNESDAY 26th
APRIL 2017, SAN FRANCISCO
3/4
14:20 New advances in RNA-therapeutics
bring RNA-seq into focus
• New advances in RNA-therapeutics bring
RNA-seq into focus
• RNA therapeutics are innovative drugs
to modulate the splicing and stability of
specific RNA sequences
• Envisagenics SpliceCoreTM is a cloud-
based platform for the discovery of
druggable splicing events
• SpliceCore combines RNA-seq analysis
with public data and machine learning to
predict disease-causing splicing events
and their regulators
Martin Akerman, CTO, Scientific Collaborator at
CSHL, Envisagenics and Cold Spring Harbor
Laboratory
Title to be confirmed
Vijay Pande, Professor, Stanford University
“An Innovative Approach to Improve
Cancer Care Through Evidence-Based
Technology: NCCN and FlatIron
collaborate on NCCN Outcomes
Database”
• Proving oncology stakeholders, the ability
to garner critical insights needed to make
informed decisions
• Electronic health record (EHR) data
aggregated for cancer quality and
outcomes assessment
• Leveraging cancer data in a meaningful
way to identify opportunities to enhance
and improve care
Lyn Fitzgerald, Senior Vice President, U.S & Global
Development at National Comprehensive Cancer
Network®, National Comprehensive Cancer
Network
Elizabeth Nardi, Quality of Oncology Care Fellow,
National Comprehensive Cancer Network
14:40 New paradigms to enhance breast
health through big data and genomics
• Using Big Data and Genomics to
understand Germline risks developing
breast cancer and triage.
• Breast cancer diagnosis and disease
genomics for treatment and prognosis
Laura van ‘t Veer, Professor Laboratory Medicine
and Associate Director Applied Genomics for the
Cancer Center at UCSF; co-founder Agendia
AI Panel
Sponsored by
Medidata
A practical approach to precision
medicine education
• Genomic literacy: Developing a minimalist
curriculum for healthcare providers, i.e.
teach me just what I need to know about
genomics to practice precision medicine
• Skills: Incorporating practical, hands on
experiences ordering tests, interpreting
reports, communicating with patients
• Awareness: Providing opportunities to
stay apprised of the latest applications of
genomics in healthcare
Jeanette McCarthy, Adjunct Associate Professor,
Duke University
15:00 Sponsored by
DxTerity
Sponsored by
ZS Associates
Afternoon refreshments15:20
15:40 FDA preparedness for “next gen
sequencing”
• It/bioinformatics tools developed at FDA
to support research and regulatory needs
• FDA research supporting regulatory
evaluation of NGS data
• FDA’s role in Precision Medicine Initiative
Carolyn Wilson, Associate Director for Research,
FDA
Sponsor Presentation Available
Do you have a solution that you would like to
share with our audience?
Contact Michael Shackil on +1.646.619.1809
or email: michael.shackil@terrapinn.com
An Australian pathway for driving PM
into the clinic.
• What are Australia’s methods for
developing a data driven precision
medicine strategy.
• New structures for the development of
precision medicine.
• Piloting new precision medicine programs
Lyn Fitzgerald, Senior Vice President, U.S & Global
Development at National Comprehensive Cancer
Network®, National Comprehensive Cancer
Network
Natalie Thorne, Clinical Bioinformatics and
Genomics Project Manager, Melbourne Genomics
Health Alliance
16:00 IT infrastructure to speed the delivery
of Precision medicine into the clinic
• Developing an efficient network
architecture to empower research
• New requirements for the big data era
• Customized working environments
Jim Broach, Director of the Penn State Institute
for Personalized Medicine, University of
Pennsylvania School of Medicine
Title to be confirmed
Olexandr Isayev, Professor, University of North
Carolina at Chapel Hill
Big Data and Genomics: Empowering
citizens to share health data through
mobile technology
• Who are the past, present, and future
health data stakeholders?
• What is the current state of health data
sharing via mobile platforms?
• In what ways do app-mediated research
studies support citizen empowerment in
research?
Megan Doerr, Principal Scientist Governance,
Sage Bionetworks
15. 16:20 Integrative analysis of high throughput
drug screening and genome-wide
expression data in Neuroblastoma
• Integrative analysis of high throughput
drug screening and genome-wide
expression data provides for:
• Testing predictive biomarkers based on
gene expression
• Development of predictive biomarkers
using machine learning
Jeffrey Bond, Lead Bioinformatician, NMTRC,
Spectrum Health System
Sponsor Presentation Available
Do you have a solution that you would like to
share with our audience?
Contact Michael Shackil on +1.646.619.1809
or email: michael.shackil@terrapinn.com
A perspective for NGS based cancer
diagnostics; assay development,
validation and compliance in the midst
of current and the future of Genomics
• Clinical trials and research while focusing
on enhancing cancer care delivery
• Improving cancer outcomes through a
targeted treatment approach
• How we respond to findings through
personalized, cancer-specific treatment
plans.
Pravin Mishra, Director, Precision Genomics Core
Laboratory & R&D, Intermountain Healthcare,
Dixie Regional Medical Center
DAY 1
WEDNESDAY 26th
APRIL 2017, SAN FRANCISCO
4/4
16:40 How the cloud is affecting big data
sharing?
• Storing communicating and tracking your
personal health records
• Patient privacy and mechanisms
• Data value and management with the
patient at the center
Andreas M. Kogelnik, Director, CEO, Open
Medicine Institute
Supercomputing and the future of
cancer
• The use of AI in drug development and
manufacture
• How BERG uses artificial intelligence to
analyze tissue samples and clinical data to
model and understand diseases and guide
drug discovery
• Understanding why AI is an overdue
disruption to drive innovation and
pharmaceutical development
Slava Akmaev, Senior Vice President & Chief
Analytics Officer, Berg Health
Joint Analysis of Many Matrices by
ITeration (JAMMIT): Tailoring precise
treatment strategies for cancers
• Breaking the analysis bottleneck that has
slowed the translation of the knowledge
within the data to the clinic
• Development of a new algorithm that
can accelerate the approval of powerful
treatments for many cancers, improve
clinical outcomes, and reduce costs for
treating cancer
• Understanding when there is a need
for specific chemotherapy based on an
algorithm
Gordon Okimoto, Co-Director, University of
Hawaii Cancer Center
17:00 Pooling knowledge worldwide through
patient family engagement can
accelerate finding therapies for rare
disease, A case study
• A new framework for empowering
undiagnosed and rare disease patient
families to participate in translational
medicine (patient families as an equal
stakeholder)
• The need for global patient outreach and
pooling of data in common platform for
undiagnosed and rare disease
• Building global collaborations - data
and research tool sharing across all
stakeholders so critical/statistical amounts
can be obtained
• The need for bringing together disease
education for diagnosis and patient
community creation, sharing of data of all
stakeholders (patient families, clinicians
and researchers) and lowering barrier to
access research tools for the community
needed to address undiagnosed and rare
disease
• Scaling to other diseases
Christina Waters, CEO, RARE
From Big Data to Precision Medicine
• Challenges of applying big data to
precision medicine
• Data integration and social implications
• Do big data derail the progress of precision
medicine?
Claudio Carini, Global Head Clinical Immunology
and Biomarkers, Pfizer
Connecting tumor genomics with
therapeutics through multi-dimensional
network modules
• Cancer cell lines can model therapeutic
responses, but only partially reflect tumor
biology.
• Using MAGNETIC, a new method to
integrate molecular profiling data using
functional networks, we identify 219
gene modules in TCGA breast cancers
that capture recurrent alterations, reveal
new roles for H3K27 tri-methylation and
accurately quantitate various cell types
within the tumor microenvironment.
• We show that a significant portion
of gene expression and methylation
in tumors is poorly reproduced in cell
lines due to differences in biology and
microenvironment and MAGNETIC
identifies therapeutic biomarkers that
are robust to these differences. This
work addresses a fundamental challenge
in pharmacogenomics that can only be
overcome by the joint analysis of patient
and cell line data
Sourav Bandyopadhyay, Assistant Professor, UCSF
Networking cocktail reception
17:20
END OF CONFERENCE DAY ONE18:30
Enabling Pediatric Precision Genomics
• Rare disease research in pediatrics requires
collaborative networks
• Networks need to enable institutions as
well as investigators
• Academic institutions benefit from
enterprise genomic data and literacy
strategies
Peter White, Director, Division of Biomedical
Informatics, Cincinnati Children’s Hospital
Medical Center
17:40
16. DAY 2
THURSDAY 27th
APRIL 2017, SAN FRANCISCO
1/3
OPENING KEYNOTE PLENARY
08:45 Opening remarks
09:20 Advancing precision medicine through collaboration and big data
• Innovation in the public sector to foster health through multiple projects including public-private partnerships
• Accelerating precision medicine in California
• Fostering a culture for collaboration and development
Elizabeth Baca, Senior Health Advisor Governor’s Office of Planning and Research, State of California Governor’s Office of Planning and Research
08:45 Making the journey from Big Data to Smart Data
Sean Khozin, Senior Medical Officer, FDA
09:40 The NCI Genomics Data Commons: making large-scale data usable
• Accessing data by download is an untenable model in the large-scale genomics era
• Data deposited in databases that do not update the alignment and/or calling as technology advances quickly becomes stale and unusable.
• The NCI Genomics Data Commons tries to solve those issues by being a constantly updated database that will allow users to do queries online
without the need to download the bulk of the raw data.
Jean Zenklusen, Director, The Cancer Genome Atlas, Centre for Cancer Genomics, Office of the Director, National Cancer Institute
Scientific Poster session and morning refreshments10:00
10:40 PANEL DISCUSSION: Data
Democratization: Empowering efficient
access and sharing of Data
James Cai, Global Head of Data Science, Roche
Andreas M. Kogelnik, Director, CEO, Open
Medicine Institute
Sàndor Szalma, Head of Data and Bioinformatics,
Takeda
GENOMICS AND HEALTH
PANEL DISCUSSION: Artificial Intelligence
for Drug Discovery, Biomarker
Development AI Pharmaceutical Strategy
Session
Tailored by Merck Pharma
ARTIFICIAL INTELLIGENCEPRECISION MEDICINE
PANEL DISCUSSION: How to drive
Precision medicine into the clinic
Chaired by: Bill Barnett, CRIO, Regenstrief and IU
School of Medicine, Regenstrief, Inc
Laura van ‘t Veer, Professor Laboratory Medicine
and Associate Director Applied Genomics for the
Cancer Center, UCSF; co-founder, Agendia
Laura Pisani, Assistant Professor, Pediatrics -
Medical Genetics, Columbia University Medical
Center
Marie-Pierre Dubé, Director, Beaulieu-Saucier
Université de Montréal Pharmacogenomics
Centre
Catherine Brownstein, Manager, Molecular
Genomics Core Facility, Boston Children’s Hospital
11:20 AstraZeneca and HLI collaboration:
Delivering precision medicine through
the sequencing 1 million genomes
• Analyzing 500,000 DNA samples from
AstraZeneca to bolster one of the most
comprehensive databases of its kind
• Transforming the way medicine is
practiced
• Streamlining drug development using big
data.
Adam Platt, Global Head of Genomics,
AstraZeneca
AI Pharmaceutical Strategy Session
Tailored by Merck Pharma
Advancing discoveries in cardiovascular
precision medicine through big data
• AHA launches MY RESEARCH LEGACY -
AN OPPORTUNITY FOR ALL INDIVIDUALS
TO ENGAGE IN LIFE LONG LEARNING
TO IMPROVE THEIR OWN HEALTH AND
THE HEALTH OF THOSE AROUND THEM,
through biosensors, technology and
community. “the Individual”
• AHA strategic partners and the “tech
platform” underneath My Research Legacy
• The data from My Research Legacy
- driving towards solutions for millions of
patients
Jennifer Hall, Chief, Institute of Precision
Cardiovascular Medicine, American Heart
Association
11.40 Understanding the non-coding genome
• How much new information do we expect
from the non-coding human genome
• Why is exome sequencing not enough?
• Where are the pathogenic variants in the
non-coding genome?
Amalio Telenti, MD, PhD, Chief Data Scientist,
Human Longevity
AI Pharmaceutical Strategy Session
Tailored by Merck Pharma
Emerging Opportunities for Genomic
Big Data Analytics in the Plecosystem
Economy
• Critical opportunities for blockchain in
Cancer Genomics: Micro-credit Accounting
for data donors, institutional data users,
ontology annotators, somatic read
annotators, decision support algorithms etc.
• Emerging methods for early detection of
onset and recurrence: The specificity/
sensitivity dilemma
• Critical need for biomarkers across the
plecosystem that help disambiguate
isolated genomic data.
John Mattison, Assistant Medical Director/CMIO,
Kaiser Permanente
17. Register online today to reserve your place! www.healthnetworkcommunications.com/biodatawest
Networking lunch12:00
DAY 2
THURSDAY 27th
APRIL 2017, SAN FRANCISCO
2/3
13:20 Realizing the transformative potential
of genomics in healthcare
• Multimodality genomics for translational
purposes
• Graphical molecular network analysis for
identification of novel disease biology
• Diagnosis and clinical care of patients with
inherited cardiovascular disease
Rick Dewey, Senior Director, Head of Translational
Genetics, Regeneron Genetics Center
The Big data hype: How to deliver next
generation research at new depths on
Migraines and Schizophrenia
• Is big data smoke and mirrors or does it
really have a place in modern healthcare
• Breaking from the conscious and
understanding data sets that are beyond
comprehension without big data.
• Seeing the big data picture and
treatment of diseases that have not been
understood until the big data revolution in
healthcare.
Aarno Palotie, Research Director, Institute for
Molecular Medicine Finland (FIMM)
Big data on a network: Massive
integration of domain knowledge to
inform drug repurposing
• Resources spent on drug development
are exorbitant. In parallel, the probabilities
of a lead compound making it to clinic are
minuscule.
• Developing a framework to integrate
millions of experimental and clinical results
in the form of a heterogeneous network,
in which drugs, diseases, genes, etc are
connected by mining a vast space of the
entire domain knowledge.
• Using Machine learning to compute the
probability that any given drug would
interfere with mechanisms of a disease
of interest (as a proxy for a potential
therapeutic).
Sergio E Baranzini, Professor Weill Institute for
Neurosciences, UCSF
13:40 Societal impacts of big data and
genomics in healthcare
• Discussing how big data has measurably
impacted our society.
• Describing current public attitudes to the
sharing of data.
• Understanding how to develop a culture of
data sharing
Cinnamon Bloss, Assistant Professor, UC San
Diego
Advancing discoveries in cardiovascular
precision medicine through big data
• Discovering the importance of
Cardiovascular precision medicine
• The current projects that are taking center
stage
• New grants
Pradyot Prasoon, Business Technology Strategist,
American Heart Association
Dr. Taha Kass-Hout, Former FDA’s 1st Chief
Health Informatics Officer, and Director, FDA Office
of Health Informatics
AI Pharmaceutical Strategy Session
Tailored by Merck Pharma
14:20 Design and implementation of
Geisinger’s first enterprise big data
platform
• Developing and managing a
comprehensive enterprise data strategy
• Modern data governance strategies
• Understanding the HPC landscape
in healthcare and pharmaceutical
development
Nicholas Marko, Founding board member of the
International Society for Chief Data Officers,
Director of Neurosurgical Oncology, Geisinger
Health System
Metagenomic next-generation
sequencing for pathogen detection
• Unbiased detection of pathogen nucleic
acid from patient samples can be achieved
through metagenomic next-generation
sequencing (mNGS).
• Broad-based organism detection requires
new approaches to validation and results
interpretation.
• This talk will discuss the precision
diagnosis of infectious disease for
meningitis/encephalitis using mNGS.
Steve Miller, Director, UCSF Clinical
Microbiology Laboratory
Blockchain, AI and pharmaceutical
development
Verner De Biasi, Head Emerging Platforms, GSK
14:00 Big data in the clinic – entering a new
legal environment
• Discussing the rapidly evolving legal and
regulatory environment big data will
encounter as it is integrated into clinical
practice
• Describing the potential legal landmines,
and techniques to avoid them
• Introducing risk management practices to
minimize risk and maximize value
James Mills Barbeau, Assoc. Professor, Brown
University Alpert Medical School, Director of
Laboratory Medicine, Lifespan Academic Medical
Center
Novel sequencing-based assays as
biomarkers of disease
• Prediction of novel biomarkers using big
data
• Genomic technologies to identify
the genetic etiology and underlying
mechanisms of human disease in order
to define precision therapies for diseased
individuals
• Predictive genomic signatures of response
to therapy, and novel sequencing-based
assays as biomarkers of disease
Ali Torkamani, Director of Genome Informatics
and Drug Discovery, The Scripps Translational
Science Institute
Sponsor Presentation Available
Do you have a solution that you would like to
share with our audience?
Contact Michael Shackil on +1.646.619.1809
or email: michael.shackil@terrapinn.com
Afternoon refreshments14:40
18. Register online today to reserve your place! www.healthnetworkcommunications.com/biodatawest
DAY 2
THURSDAY 27th
APRIL 2017, SAN FRANCISCO
3/3
15:20 Developing Inova’s IT infrastructure
to support the collection, storage,
visualization and distribution of
genomic, clinical and laboratory data
• How do you handle data governance?
• What infrastructure tools do you use to
acquire, quality control and visualize your
data?
• Who are your key data consumers?
Aaron Black, Director of Informatics, Inova
Translational Medicine Institute
Data Blitz
6 min AI startup talks.
1. Benevolent AI
2. Deep Genomics
3. Inventis
4. Atomwise
Discovering drivers of immune response
to cancer discovered through ‘big data’
analysis
• 100 new genetic regions that affect the
immune response to cancer.
• New directions for cancer immunology
research
• Developing the DomainXplorer
Adam Godzik, Director, Sanford-Burnham
Medical Research Institute
15:40 Next generation medical records, based
on the human genome
• Developing approaches for the diagnosis
of difficult-to-solve medical cases
• Harnessing a greater understanding of
rare diseases
• Developing novel cures
Daryl Waggot, Data Scientist, Stanford
University
Driving next generation diagnostics and
precision medicine into the clinic
• Translational aspects of targeted therapy
and molecular diagnostics.
• New software that will support next-
generation sequencing panels to identify
more targeted treatments for tumor types
• Effective management of large volumes of
genetic data through a scalable system
Anna Berry, Scientific Director of Personalized
Medicine and Medical Director of Molecular
Diagnostics, Swedish Cancer Institute
16:00 Genomics and Health: Transferring the
power of HPC & NGS to the clinic
• Methods for next generation diagnostics
• Implications of big data in the clinic a case
study review
• Big Data and ethics
Catherine Brownstein, Manager, Molecular
Genomics Core Facility, Boston Children’s
Hospital
When small data = big data, or the magic
of transfer learning.
• Sharing and connecting deep learning
algorithms algorithms to create conditions
for a cross-fertilization between powerful
artificial intelligence systems?
• Transfer learning to foster collaborative AI
• How to bring big-data-trained deep
learning algorithms into the world of
medical data
• How collaborative AI can bring new
business models to create value with data
Gilles Wainrib, co-founder, OWKIN
Genetic modulators of the efficacy and
safety of cardiovascular medications
• Review of the current state of genetic
modulators of cardiovascular drugs
• Performing genomic studies of completed
cardiovascular clinical trials
• Update on the Montreal Heart Institute
genomic work with lipid trials
Marie-Pierre Dubé, Director, Beaulieu-Saucier
Université de Montréal Pharmacogenomics
Centre
16:20 Cannabis Strains and regulation
• Understanding the current issues with
regulation in cannabis
• Producing and monitoring cannabis using
databases and block chain
• Big Data and Cannabis
Kevin McKernan, Head of Research, Courtagen
Life Sciences Inc
Automated Genome-Based Prediction
tool for Pathogens for the prediction
of complex virulence and antibiotic
resistance phenotypes using high
throughput sequencing data
• Detection of antibiotic resistance
phenotypes using high throughput
sequencing data.
• Machine learning algorithms to determine
the diverse features (change in virulence
genes, recombination, horizontal gene
transfer, patient diagnostics).
• Pathogenic Potential and
Countermeasures Targets
Debjit Ray, Postdoctoral researcher, Sandia
National Labs
Finding a needle in a haystack: new
approaches to discover disease-causing
mutations in patients’ genomes
• The value of the whole genome rather
than exome
• The human gene damage index
• Filtering out false positives
Yuval Itan, Research Associate, Rockefeller
University
CLOSE OF CONFERENCE16:40
20. Here’s an overview of the floor plan. See the website for the most up-to-date
version.
What this means for your business:
Emerging science, technologies and
collaborations are needed to make the necessary
moves forward. As a provider of solutions to
these issues, the event will provide a space for
you to get in front of potential new customers
from all walks of the precision medicines
industry.
Your customers will be there to:
• Hear insights from the world’s leading
thinkers, practitioners and process disrupters
• Evaluate and buy the latest tecnologies
• Create new partnerships and gain investment
• Have fun and do business
What a great opportunity to:
• Debut new solutions
• Improve your brand awareness
• Meet new prospective clients
• Maintain relationships
Pursue, partner and have fun:
• 200+ participants
• Thousands of formal and informal meetings
over just three days
• 30+ scientific posters
• Career Corner recruitment zone
• Two engaging networking lunches
• Two networking drinks receptions
• Gala Dinner
Who should sponsor? Companies providing solutions in:
To exhibit, sponsor or speak at this year’s event call Michael Shackil at
+1 646 619 1809 or email michael.shackil@terrapinn.com
THE EXHIBITION
Data mining/
analysis
Gene sequencing
platforms
Implementation
partners and
systems
integrators
Data storage/
management
High throughput
technology
providers
IT infrastructure
Enterprise
resource planning
Cloud computing
and hosting
Artificial
Intelligence
21. 11
13
14
7
6
910
1 2 3 4 5
812
15
Streams 2 & 3
Stream 1
Exhibition
GARDEN LEVELLOBBY LEVEL
Register
Refreshments
Plenary Room
To exhibit, sponsor or speak call Michael Shackil at
+1 646 619 1809 or email michael.shackil@terrapinn.com
SUPPORTERS
FLOORPLAN
23. 1. Hear from Atul Butte, Director, Institute for
Computational Health Sciences, University
of California, San Francisco as he presents
a historic keynote on bringing Big Data and
Genomics together to unlock cures for rare
diseases
2. Discover how AI is changing the face of medicine
with Merck
3. Witness how genomic medicine is transforming
the clinic with the US Department of Veteran
Affairs
4. Uncover advances in precision medicine from across
the globe in countries like the US, Singapore,
Australia, Canada, Sweden, and Finland
5. Learn how technology is empowering citizens
to share health data through mobile technology
with Megan Doerr, Principal Scientist Governance,
Sage Bionetworks
6. Gain insight from pharma on the challenges of
applying big data to precision medicine with
Pfizer and Kaiser Permanente
7. Hear case studies on how big data can drive
personalized medicine with Duke University,
Melbourne Genomics Health Alliance,
American Heart Association, and the Scripps
Translational Science Institute
8. Collaborate with government, healthcare
institutions and regulatory bodies such as the
FDA, NIH, and National Cancer Institute to
break down barriers to innovation and research
9. Cancer - With genomics are we one step
closer to a cure? Hear the latest from
University of Melbourne Centre for Cancer
Research, U.C.S.C, Ohio State University
Comprehensive Cancer Center, Cancer LinQ,
National Comprehensive Cancer Network,
National Cancer Institute and more
10. Meet, discuss research, and do business with
hundreds of other industry leaders using the
Jublia Networking System, where you can search
not just by name and title, but by the content of
their work.
Industries attending
Job titles
WHO ATTENDS
Reasons to attend:
Don’t hesitate – register now!
www.healthnetworkcommunications.com/
biodatawest
Pharma/Biotech
31%
Universities
9%
Charities/Associations
7%
Hospitals/Public Health
15%
Service providers
18%
Research Institutes
20%
22%
Manager
16%
VP
35%
Director
27%
Head
24. WEBSITE
Our website is fully responsive and is updated regularly
EMAIL MARKETING
We run a sophisticated lead generation and lead nurture campaign to our comprehensive database.
DIGITAL ADVERTISING
A comprehensive digital campaign will be run using google and facebook advertising. Re-targeting
will be used extensively.
INBOUND MARKETING
Our team regularly blog on our blog, ebooks will be produced for download and lead generation.
SOCIAL MARKETING
Blog posts and event alerts are regularly posted to our dedicated facebook page, twitter feed and
linkedin group. And they are posted to relevant 3rd party groups and pages.
PRESS AND 3RD PARTY CAMPAIGN
We will be partnering with leading press and media. Digital advertising, email blasts and page adverts
will be placed in the run up to the event.
DIRECT SALES
Our dedicated direct sales team ensures that no lead is left unconverted. As a sponsor or exhibitor at
the BioData Congress West you can leverage our marketing campaign:
• Your logo will be prominent on all marketing materials
• You can benefit from our inbound marketing machine and post blogs and content to the site
Our marketing campaign kicks off twelve months out and is a fully integrated digital
campaign using a variety of channels:
Our marketing campaign has started.
To start taking advantage of it, call Michael Shackil at
+1 646 619 1809 or email michael.shackil@terrapinn.com
AN INTEGRATED MARKETING
CAMPAIGN FOR CLIENTS
25. The earlier you book, the more you’ll save.
Your next steps towards building an effective presence at
the event begins now.
RESERVE YOUR PLACE
Package TIER 1 TIER 2 TIER 3
Full Conference pass $1,600 $1,800 $2,000
Group of 3 $1,120 per person $1,260 per person $1,400 per person
Michael Shackil
on +1 646 619 1809 or email
michael.shackil@terrapinn.com
